Monoclonal antibody with conformational specificity for a toxic conformer of amyloid β42 and its application toward the Alzheimer’s disease diagnosis

• Published in: Scientific reports Vol. 6; no. 1; p. 29038
• Main Authors: Murakami, Kazuma, Tokuda, Maki, Suzuki, Takashi, Irie, Yumi, Hanaki, Mizuho, Izuo, Naotaka, Monobe, Yoko, Akagi, Ken-ichi, Ishii, Ryotaro, Tatebe, Harutsugu, Tokuda, Takahiko, Maeda, Masahiro, Kume, Toshiaki, Shimizu, Takahiko, Irie, Kazuhiro
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 04.07.2016; Nature Publishing Group
• Subjects: 101/1; 631/378/1689; 631/92/611; 82; 82/1; Aged; Aged, 80 and over; Alzheimer Disease - cerebrospinal fluid; Alzheimer Disease - diagnosis; Amyloid beta-Peptides - cerebrospinal fluid; Amyloid beta-Peptides - immunology; Amyloid beta-Peptides - toxicity; Animals; Antibodies, Monoclonal - cerebrospinal fluid; Antibodies, Monoclonal - chemistry; Case-Control Studies; Cell Line, Tumor; Cells, Cultured; Female; Humanities and Social Sciences; Humans; Male; Molecular Conformation; multidisciplinary; Neurons - drug effects; Neurons - metabolism; Peptide Fragments - cerebrospinal fluid; Peptide Fragments - immunology; Peptide Fragments - toxicity; Rats, Wistar; Science; Science (multidisciplinary); Surface Plasmon Resonance

Amyloid β-protein (Aβ42) oligomerization is an early event in Alzheimer’s disease (AD). Current diagnostic methods using sequence-specific antibodies against less toxic fibrillar and monomeric Aβ42 run the risk of overdiagnosis. Hence, conformation-specific antibodies against neurotoxic Aβ42 oligome...